Literature DB >> 32470524

Complex relationship between low albumin level and poor outcome after lower extremity procedures for peripheral artery disease.

Jonathan Bath1, Jamie B Smith2, Jennifer Woodard3, Robin L Kruse2, Todd R Vogel4.   

Abstract

OBJECTIVE: A low albumin level has been associated with poor outcome, including death, in surgical patients. The mechanistic relationship, however, is more complex than simply nutritional. As studies are scant in the vascular population, we sought to examine the association of low albumin level with outcomes in patients undergoing open and endovascular lower extremity procedures for peripheral artery disease.
METHODS: Patients with peripheral artery disease undergoing lower extremity procedures (2008-2015) were selected from Cerner Health Facts database (Cerner Corporation, Kansas City, Mo) using International Classification of Diseases, Ninth Revision diagnosis and procedure codes. Age, sex, disease severity, and other comorbidities were captured. Outcomes were identified using codes and encounter data. A χ2analysis and multivariable logistic regression were performed.
RESULTS: There were 6170 patients evaluated; 4562 (74%) underwent endovascular procedures and 1608 (26%) underwent open surgery. Low albumin level (<3.5 g/dL) was associated with age ≥80 years (23.1% vs 16.3% normal; P < .0001), black race (21% vs 11.6% normal; P < .0001), tissue loss (38% vs 16.4% normal; P < .0001), and higher Charlson index (mean, 3.1 vs 2.2 in the normal group; P < .0001). Low albumin level was also associated with longer length of stay (4.9 vs 2.2 days normal; P < .0001), higher in-hospital mortality (1.9% vs 0.3% normal; P < .0001), and higher 30-day readmission (15% vs 12.7% normal; P = .02). Multivariable analysis demonstrated that low albumin level was strongly associated with in-hospital death (odds ratio [OR], 5.23; 95% confidence interval [CI], 2.00-13.70), infection (OR, 2.51; 95% CI, 1.96-3.22), renal failure (OR, 2.61; 95% CI, 1.79-3.79), and cardiac complications (OR, 2.59; 95% CI, 1.69-3.96). After multivariable adjustment, there was no association between albumin level and 30-day readmission.
CONCLUSIONS: Low preoperative albumin levels are associated with in-hospital death, prolonged length of stay, and severe morbidity after open and endovascular lower extremity procedures. As the majority of lower extremity procedures are elective, serious consideration should be given to deferring elective procedures until albumin levels have been optimized. Because of the pleiotropic effects of albumin, including antiplatelet and inflammatory function, study of this complex relationship may offer insights into how best to integrate this novel biomarker into vascular surgery decision-making.
Copyright © 2020 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Albumin; Morbidity; Mortality; Outcome; Peripheral arterial disease

Mesh:

Substances:

Year:  2020        PMID: 32470524      PMCID: PMC7688476          DOI: 10.1016/j.jvs.2020.04.524

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  33 in total

1.  National health care costs of peripheral arterial disease in the Medicare population.

Authors:  Alan T Hirsch; Lacey Hartman; Robert J Town; Beth A Virnig
Journal:  Vasc Med       Date:  2008-08       Impact factor: 3.239

2.  Rehospitalizations among patients in the Medicare fee-for-service program.

Authors:  Stephen F Jencks; Mark V Williams; Eric A Coleman
Journal:  N Engl J Med       Date:  2009-04-02       Impact factor: 91.245

3.  Albumin research in the 21st century.

Authors:  Theodore Peters; Alan J Stewart
Journal:  Biochim Biophys Acta       Date:  2013-12

Review 4.  Acute-phase proteins and other systemic responses to inflammation.

Authors:  C Gabay; I Kushner
Journal:  N Engl J Med       Date:  1999-02-11       Impact factor: 91.245

Review 5.  Human serum albumin, systemic inflammation, and cirrhosis.

Authors:  Vicente Arroyo; Rita García-Martinez; Xavier Salvatella
Journal:  J Hepatol       Date:  2014-04-18       Impact factor: 25.083

6.  Role of nutritional indices in predicting outcomes of vascular surgery.

Authors:  Jana Jabbour; Adham N Abou Ali; Wissam Rabeh; Laila Al-Shaar; Efthymios D Avgerinos; Robert H Habib
Journal:  J Vasc Surg       Date:  2019-03-25       Impact factor: 4.268

7.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

Review 8.  Serum albumin: relationship to inflammation and nutrition.

Authors:  Burl R Don; George Kaysen
Journal:  Semin Dial       Date:  2004 Nov-Dec       Impact factor: 3.455

9.  Risk Factors for 30-Day Hospital Re-Admission with an Infectious Complication after Lower-Extremity Vascular Procedures.

Authors:  Joseph C Melvin; Jamie B Smith; Robin L Kruse; Todd R Vogel
Journal:  Surg Infect (Larchmt)       Date:  2017-02-08       Impact factor: 2.150

10.  The UK Cardiac and Vascular Surgery Interventional Anaemia Response (CAVIAR) Study: protocol for an observational cohort study to determine the impact and effect of preoperative anaemia management in cardiac and vascular surgical patients.

Authors:  Marisa Chau; Toby Richards; Caroline Evans; Anna Butcher; Timothy Collier; Andrew Klein
Journal:  BMJ Open       Date:  2017-04-18       Impact factor: 2.692

View more
  2 in total

1.  Predictive Value of Geriatric Nutritional Risk Index in Patients With Lower Extremity Peripheral Artery Disease: A Meta-Analysis.

Authors:  Guodong Liu; Chen Zou; Yu Jie; Pei Wang; Xiaoyan Wang; Yu Fan
Journal:  Front Nutr       Date:  2022-06-22

Review 2.  Nutritional Assessment and Interventions in Elective Hip and Knee Arthroplasty: a Detailed Review and Guide to Management.

Authors:  Michael D Dubé; Christopher A Rothfusz; Ahmed K Emara; Matthew Hadad; Peter Surace; Viktor E Krebs; Robert M Molloy; Nicolas S Piuzzi
Journal:  Curr Rev Musculoskelet Med       Date:  2022-05-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.